Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jun;11(6):708-715.
doi: 10.1002/mdc3.14051. Epub 2024 May 2.

Hyperkinetic Movement Disorder Caused by the Recurrent c.892C>T NACC1 Variant

Jonna Komulainen-Ebrahim  1   2   3 , Salla M Kangas  1   2   4 , Estrella López-Martín  5 , Timothy Feyma  6 , Fernando Scaglia  7   8   9 , Beatriz Martínez-Delgado  5 , Outi Kuismin  1   2   10 , Maria Suo-Palosaari  2   11   12 , Lucinda Carr  13 , Reetta Hinttala  1   2   4 , Manju A Kurian  13   14 , Johanna Uusimaa  1   2   3
Affiliations
Case Reports

Hyperkinetic Movement Disorder Caused by the Recurrent c.892C>T NACC1 Variant

Jonna Komulainen-Ebrahim et al. Mov Disord Clin Pract. 2024 Jun.

Abstract

Background: Genetic syndromes of hyperkinetic movement disorders associated with epileptic encephalopathy and intellectual disability are becoming increasingly recognized. Recently, a de novo heterozygous NACC1 (nucleus accumbens-associated 1) missense variant was described in a patient cohort including one patient with a combined mitochondrial oxidative phosphorylation (OXPHOS) deficiency.

Objectives: The objective is to characterize the movement disorder in affected patients with the recurrent c.892C>T NACC1 variant and study the NACC1 protein and mitochondrial function at the cellular level.

Methods: The movement disorder was analyzed on four patients with the NACC1 c.892C>T (p.Arg298Trp) variant. Studies on NACC1 protein and mitochondrial function were performed on patient-derived fibroblasts.

Results: All patients had a generalized hyperkinetic movement disorder with chorea and dystonia, which occurred cyclically and during sleep. Complex I was found altered, whereas the other OXPHOS enzymes and the mitochondria network seemed intact in one patient.

Conclusions: The movement disorder is a prominent feature of NACC1-related disease.

Keywords: NACC1; cyclic; hyperkinetic; movement disorder.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Cellular phenotype, nucleus accumbens‐associated protein 1 (NACC1) expression and expression, function, and assembly of mitochondrial complexes were studied in patient‐derived fibroblasts. (A) Patient‐derived fibroblasts from patient 1 have normal cell morphology and NACC1 is localized in the nucleus; a faint signal is observed in the cytoplasm both in patient‐derived cells and controls. Tom20 antibody was used to visualize the mitochondrial network, which appears normal in patient‐derived cells. Phalloidin:FITC was used to visualize actin cytoskeleton. Images were taken using 63× magnification. (B) Heterozygous expression of nucleus accumbens‐associated 1 (NACC1) c.892C>T variant in patient‐derived fibroblasts was verified using reverse transcription polymerase chain reaction (RT‐PCR) and Sanger sequencing. (C) Immunoblotting of cell lysates from patient‐derived (P) and control (C) fibroblasts with NACC1‐specific antibody. GAPDH was used as loading control. (D) NACC1 levels normalized to GAPDH revealed normal amount of 57‐kDa band detected by NACC1 antibody in patient fibroblasts (P) compared to controls (C). (E) NACC1 gene expression level in patient‐derived cells was studied using quantitative PCR and it did not differ from the control cells. (F,G) Blue Native polyacrylamide gel electrophoresis and protein quantification derived from the western blot method indicated that complex I level in patient cells was 1.5‐fold compared to the control fibroblasts (P < 0.05, two‐tailed Student's t test). Other mitochondrial complexes were expressed at a normal level in patient‐derived fibroblasts. The levels of the marker proteins representative of mitochondrial complexes encoded by mitochondrial DNA were normalized to succinate dehydrogenase complex flavoprotein subunit A (SDHA), thereby representing complex II, which is encoded by the nuclear genome. (H,I) In‐gel activity assay to measure complex I function showed normal function in patient‐derived fibroblasts when compared to two control cell lines. Signal intensity was normalized to control 1 (C1) fibroblast line. Error bars in the images indicate standard deviation.
See this image and copyright information in PMC

Similar articles

  • A New Case of de novo Variant c.892C>T (p.Arg298Trp) in NACC1: A First Case Report From China.
    Lyu B, Dong Y, Kang J. Lyu B, et al. Front Pediatr. 2021 Nov 15;9:754261. doi: 10.3389/fped.2021.754261. eCollection 2021. Front Pediatr. 2021. PMID: 34869110 Free PMC article.
  • A Recurrent De Novo Variant in NACC1 Causes a Syndrome Characterized by Infantile Epilepsy, Cataracts, and Profound Developmental Delay.
    Schoch K, Meng L, Szelinger S, Bearden DR, Stray-Pedersen A, Busk OL, Stong N, Liston E, Cohn RD, Scaglia F, Rosenfeld JA, Tarpinian J, Skraban CM, Deardorff MA, Friedman JN, Akdemir ZC, Walley N, Mikati MA, Kranz PG, Jasien J, McConkie-Rosell A, McDonald M, Wechsler SB, Freemark M, Kansagra S, Freedman S, Bali D, Millan F, Bale S, Nelson SF, Lee H, Dorrani N; UCLA Clinical Genomics Center; Undiagnosed Diseases Network; Goldstein DB, Xiao R, Yang Y, Posey JE, Martinez-Agosto JA, Lupski JR, Wangler MF, Shashi V. Schoch K, et al. Am J Hum Genet. 2017 Feb 2;100(2):343-351. doi: 10.1016/j.ajhg.2016.12.013. Epub 2017 Jan 26. Am J Hum Genet. 2017. PMID: 28132692 Free PMC article.
  • Nacc1 Mutation in Mice Models Rare Neurodevelopmental Disorder with Underlying Synaptic Dysfunction.
    Deehan MA, Kothuis JM, Sapp E, Chase K, Ke Y, Seeley C, Iuliano M, Kim E, Kennington L, Miller R, Boudi A, Shing K, Li X, Pfister E, Anaclet C, Brodsky M, Kegel-Gleason K, Aronin N, DiFiglia M. Deehan MA, et al. J Neurosci. 2024 Apr 3;44(14):e1610232024. doi: 10.1523/JNEUROSCI.1610-23.2024. J Neurosci. 2024. PMID: 38388424
  • An intellectual-disability-associated mutation of the transcriptional regulator NACC1 impairs glutamatergic neurotransmission.
    Daniel JA, Elizarova S, Shaib AH, Chouaib AA, Magnussen HM, Wang J, Brose N, Rhee J, Tirard M. Daniel JA, et al. Front Mol Neurosci. 2023 Jul 14;16:1115880. doi: 10.3389/fnmol.2023.1115880. eCollection 2023. Front Mol Neurosci. 2023. PMID: 37533751 Free PMC article. Review.
  • GNAO1-Related Disorder.
    Briere L, Thiel M, Sweetser DA, Koy A, Axeen E. Briere L, et al. 2023 Nov 9. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2023 Nov 9. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 37956232 Free Books & Documents. Review.
See all similar articles

References

    1. Sanger TD, Chen D, Fehlings DL, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord 2010;25(11):1538–1549. - PMC - PubMed
    1. Kurian MA, Dale RC. Movement disorders presenting in childhood. Continuum (Minneap Minn) 2016;22(4):1159–1185. - PubMed
    1. Koene S, Rodenburg RJ, van der Knaap MS, et al. Natural disease course and genotype–phenotype correlations in complex I deficiency caused by nuclear gene defects: what we learned from 130 cases. J Inherit Metab Dis 2012;35(5):737–747. - PMC - PubMed
    1. Cordeiro D, Bullivant G, Siriwardena K, Evans A, Kobayashi J, Cohn RD, Mercimek‐Andrews S. Genetic landscape of pediatric movement disorders and management implications. Neurol Genet 2018;4(5):e265. - PMC - PubMed
    1. Carecchio M, Mencacci NE. Emerging monogenic complex hyperkinetic disorders. Curr Neurol Neurosci Rep 2017;17:97. - PMC - PubMed

Publication types

LinkOut - more resources